| Methods |
C = randomisation not described
Patient, doctor and assessments blinded
Exclusions during the trial: none
Losses to FU: 5 participants |
| Participants |
North America
171 participants
Mean age 65 years
100% CT before entry
Mild to moderate ischaemic stroke NIHSS 7 to 22
Less than 12 hours since onset |
| Interventions |
Rx: argatroban 100 mcg/kg bolus, followed by low‐dose arm 1 mcg/kg/min or high‐dose arm 3 mcg/kg/min for 5 days versus placebo
Control: aspirin use in both arms |
| Outcomes |
Death
Symptomatic ICH
Major extracranial ICH
Barthel, NIHSS, MRS at 90 days |
| Notes |
Ex: age > 85
BP: > 220/130
FU: 30 days, 90 days |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
B ‐ Unclear |
